BriaCell Therapeutics (TSE:BCT) Stock Price Up 0.9% – Time to Buy?

BriaCell Therapeutics Corp. (TSE:BCT) shares were up 0.9% during mid-day trading on Thursday . The company traded as high as C$5.77 and last traded at C$5.73. Approximately 23,384 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 43,565 shares. The stock had previously closed at C$5.68.

BriaCell Therapeutics Trading Down 0.5%

The stock has a fifty day moving average of C$10.20 and a two-hundred day moving average of C$12.12. The company has a market capitalization of C$35.40 million, a PE ratio of -0.17 and a beta of 2.15.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.